David DiLillo
Executive Director Regeneron Pharmaceuticals
David DiLillo is a broadly-trained immunologist with more than 24 years of experience in basic and translational biomedical sciences. He brings expertise in the areas of tumor immunology, infectious disease, and autoimmunity, with particular emphasis in immuno-oncology, T cell-engaging antibodies, adoptive cellular therapies (CAR T and TCR T), antibody biology/engineering, Fc-receptor biology, B- and T-lymphocyte biology, and immunological regulatory mechanisms.
Seminars
Tuesday 19th May 2026
Next-Generation HLA/Peptide-Targeted Therapies: Lessons Learned from Comparing TCR-T Versus TCR Mimetic CAR-T
2:00 pm
- State-of-the-art techniques for discovering tumor-specific HLA/peptide targets and technologies for generating TCRs and TCR mimetic antibodies
- Directly compare and contrast TCR-T versus TCR mimetic CAR-T cells in vitro and in vivo
- Engineering T-cells and combinations with biologics for optimal deployment of HLA/ peptide-targeted therapies in the clinic
New Data
